Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Comparative, Randomized, Multicenter Phase IV Clinical Study to Evaluate the Clinical Efficacy and Safety of the Drug Ranquilon, Tablets, 1 mg, in Patients With Anxiety Disorders Due to Neurasthenia and Adjustment Disorders

NCT06843044 is registered in ClinicalTrials.gov with Valenta Pharm JSC as lead sponsor.

NCT NCT06843044
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06843044 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Comparative, Randomized, Multicenter Phase IV Clinical Study to Evaluate the Clinical Efficacy and Safety of the Drug Ranquilon, Tablets, 1 mg, in Patients With Anxiety Disorders Due to Neurasthenia and Adjustment Disorders
Lead sponsor
Valenta Pharm JSC
Phase
Phase 4
Overall status
Recruiting
Start date
January 13, 2025
Completion date
December 31, 2027
Enrollment
250 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

adjustment disorders, anxiety, neurasthenia